JMP Securities initiated coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) in a report released on Wednesday,Briefing.com Automated Import reports. The brokerage set an "outperform" rating and a $33.00 price target on the stock. JMP Securities' price objective suggests a potential upside of 297.59% from the company's previous close.

ABVX opened at $8.30 on Wednesday. The firm has a 50-day moving average price of $9.95 and a 200-day moving average price of $11.67. ABIVAX Société Anonyme has a twelve month low of $8.06 and a twelve month high of $17.02.

Several hedge funds have recently bought and sold shares of ABVX. Point72 Asset Management L.P. raised its stake in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock worth $6,254,000 after acquiring an additional 119,300 shares in the last quarter. abrdn plc raised its stake in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after acquiring an additional 198,225 shares in the last quarter. Walleye Capital LLC raised its stake in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after acquiring an additional 80,807 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock worth $150,000 after acquiring an additional 5,900 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider ABIVAX Société Anonyme, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.

While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.